Registry-listed formulations

Flutemetamol (18F) · chembl:CHEMBL2042122

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

14 source entries across 10 studies. This list may not include all unresolved or historical entries.

VIZAMYL 400 MBq/mL solution for injectionRegistry product
Linked study entry; product equivalence not established
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Linked study entry; product equivalence not established
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Linked study entry; product equivalence not established
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Linked study entry; product equivalence not established
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source
VIZAMYL 400 MBq/mL solution for injectionRegistry product
Molecular identity unconfirmed
Formulation reported by source: SOLUTION FOR INJECTION
Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.
View study and source

Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

3(60%)

Results Posted

100%(1 trials)

Phase Distribution

Phase 4

20%

Phase 2

40%

Phase 3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(1)

Other(1)

Detailed Status

Recruiting3

Completed1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (50.0%)

Phase 31 (25.0%)

Phase 41 (25.0%)

Trials by Status

completed120%

recruiting360%

unknown120%

Recent Activity

3 active trials

Showing 5 of 5

recruiting

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

NCT02685969

completedphase_3

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

NCT02164643

unknownphase_2

Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis

SYF0bfa662ed75d429787ed7d3f06370d7a

recruitingphase_4

Patient- and care-related benefits of amyloid PET imaging (ENABLE)

SYF1b813f52676b4e8c82d2b62df97fffd8

recruitingphase_2

Amyloid pathology in cognitively normal elderly subjects (PreclinAD)

SYF51cf893c0369442f810eef89744867d5

Clinical Trials (5)

Showing 5 of 5 trials

NCT02685969

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

Recruiting

NCT02164643Phase 3

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

Completed

SYF0bfa662ed75d429787ed7d3f06370d7aPhase 2

Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis

Unknown

SYF1b813f52676b4e8c82d2b62df97fffd8Phase 4

Patient- and care-related benefits of amyloid PET imaging (ENABLE)

Recruiting

SYF51cf893c0369442f810eef89744867d5Phase 2

Amyloid pathology in cognitively normal elderly subjects (PreclinAD)

Recruiting

All 5 trials loaded